<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00122681</url>
  </required_header>
  <id_info>
    <org_study_id>580299/008</org_study_id>
    <nct_id>NCT00122681</nct_id>
  </id_info>
  <brief_title>Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18</brief_title>
  <official_title>A Phase III, Double-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and
      genitals in men and women. Several types of HPV infection are transmitted by sexual activity
      and, in women, can infect the cervix (part of the uterus or womb). This infection often goes
      away by itself, but if it does not go away (this is called persistent infection), it can lead
      in women over a long period of time to cancer of the cervix. If a woman is not infected by
      HPV, it is very unlikely that she will get cervical cancer. This study will evaluate the
      efficacy of GSK Biologicals HPV 16/18 VLP/AS04 vaccine to prevent infection associated
      cervical pre-cancer and vaccine with HPV 16 or 18 and the vaccine safety, over 48 months, in
      young adolescents and women of 15/25 years of age at study start. Approximately 18.000 study
      subjects will either receive the HPV vaccine or a control vaccine (hepatitis A vaccine)
      administered intramuscularly according to a 0-1-6 month schedule.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NOTE: Some 178 centers participate in this study. Given that the recruitment is completed,
      the researchers have listed one center per country in this website. If required, further
      details of centers available on request.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2004</start_date>
  <completion_date type="Actual">November 26, 2009</completion_date>
  <primary_completion_date type="Actual">November 3, 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection in Subjects HPV DNA Negative and Seronegative at Baseline or Overall (Any Serostatus at Baseline)</measure>
    <time_frame>Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post-dose 3</time_frame>
    <description>CIN2+ was defined as CIN grades 2 and 3, endocervical adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done in:
DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection in Subjects HPV DNA Negative and Seronegative at Baseline or Overall (Any Serostatus at Baseline)</measure>
    <time_frame>at Month 48</time_frame>
    <description>CIN2+ was defined as CIN grades 2 and 3, endocervical adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done in subjects:
DNA- and sero-: HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen</measure>
    <time_frame>Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post dose 3</time_frame>
    <description>CIN1+ was defined as histopathologically-confirmed lesions including cervical intraepithelial neoplasia of grade 1 (CIN1), grade 2 (CIN2), grade 3 (CIN3), AIS and invasive cervical cancer.
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and General Symptoms</measure>
    <time_frame>Within 7 days after any vaccination</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include arthralgia, fatigue, fever (measured in degree celsius (Â°C) by axillary route), gastrointestinal symptoms, headache, myalgia, rash and urticaria.
Data are presented across the 3 doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events</measure>
    <time_frame>Within 30 days after any vaccination</time_frame>
    <description>Unsolicited adverse event (AE) covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>Throughout the entire study period (Month 0 to Month 48)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting New Onset of Chronic Disease (NOCDs)</measure>
    <time_frame>Throughout the entire study (Month 0 to 48)</time_frame>
    <description>NOCDs include autoimmune disorders, asthma, type I diabetes, allergies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Medically Significant Conditions</measure>
    <time_frame>Throughout entire study period (Month 0 to Month 48)</time_frame>
    <description>Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Outcome of Pregnancies, Overall and Stratified by Initial (Month 0) HPV-16/18 DNA Status and According to HPV-16 or -18 Serostatus</measure>
    <time_frame>Throughout the entire study period (Month 0 to Month 48)</time_frame>
    <description>Pregnancy outcomes are normal infant, premature infant, abnormal infant, elective termination, therapeutic abortion, ectopic pregnancy, spontaneous abortion, still birth, lost to follow-up, no pregnancy/molar pregnancy, pregnancy ongoing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18</measure>
    <time_frame>Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post dose 3</time_frame>
    <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18</measure>
    <time_frame>at Month 48</time_frame>
    <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types</measure>
    <time_frame>Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post dose 3</time_frame>
    <description>Oncogenic types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline regardless of initial serostatus.
HRW-HPV= All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HR-HPV= High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types</measure>
    <time_frame>at Month 48</time_frame>
    <description>Oncogenic types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline regardless of initial serostatus.
HRW-HPV = All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HR-HPV = High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen</measure>
    <time_frame>at Month 48</time_frame>
    <description>CIN1+ was defined as histopathologically-confirmed lesions including cervical intraepithelial neoplasia of grade 1 (CIN1), grade 2 (CIN2), grade 3 (CIN3), AIS and invasive cervical cancer.
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Persistent Infection (12-month Definition) With HPV-16 or HPV-18</measure>
    <time_frame>Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post dose 3</time_frame>
    <description>Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type (by PCR) over a 12-month interval (evaluations were planned at approximately 6-month intervals).
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Persistent Infection (12-month Definition) With HPV-16 or HPV-18</measure>
    <time_frame>at Month 48</time_frame>
    <description>Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type (by PCR) over a 12-month interval (evaluations were planned at approximately 6-month intervals).
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen</measure>
    <time_frame>Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post dose 3</time_frame>
    <description>Oncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline regardless of initial serostatus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen</measure>
    <time_frame>at Month 48</time_frame>
    <description>Oncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline regardless of initial serostatus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen</measure>
    <time_frame>Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post dose 3</time_frame>
    <description>CIN2+ was defined as histopathologically-confirmed lesions including cervical intraepithelial neoplasia of grade 2 (CIN2), grade 3 (CIN3), AIS and invasive cervical cancer.
Oncogenic types detected included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline, regardless of initial serostatus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen</measure>
    <time_frame>at Month 48</time_frame>
    <description>CIN2+ was defined as histopathologically-confirmed lesions including cervical intraepithelial neoplasia of grade 2 (CIN2), grade 3 (CIN3), AIS and invasive cervical cancer.
Oncogenic types detected included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline, regardless of initial serostatus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Anti-HPV-16 and Anti-HPV-18 Antibody Titers by ELISA in the Immunogenicity Subset, According to Initial (Month 0) HPV-16 or HPV-18 Serostatus</measure>
    <time_frame>At Months 6, 7, 12, 24, 36 &amp; 48</time_frame>
    <description>Cut-off values assessed for seropositivity include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.
Results are presented for the total group and stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus by ELISA - seronegative (sero-) or seropositive (sero+)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HPV-16 and Anti-HPV-18 ELISA Titers in the Immunogenicity Subset</measure>
    <time_frame>At Months 6, 7, 12, 24, 36 and 48</time_frame>
    <description>Titers are given as Geometric Mean Titers (GMTs) expressed as ELISA Units per milliliter (EL.U/mL).
GMTs are presented for the total group and also stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus by ELISA [seronegative (sero-) or seropositive (sero+)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV-16 and HPV-18 Seroconversion (V5/J4 Monoclonal Inhibition Test)</measure>
    <time_frame>Month 0, 7, 12 and 24</time_frame>
    <description>HPV-16 V5 cut-off was defined as greater than or equal to 41 ELU/mL. Only seronegative subjects were analysed. Seronegative subjects are subjects who had an antibody titer of less than 41 ELU/mL before vaccination.
HPV-18 J4 cut-off was defined as greater than or equal to 110 EL.U/mL. Both seropositive and seronegative subjects were included in the analysis. Seropositive subjects were subjects with an antibody titer of greater than or equal to 110 EL.U/mL. Seronegative subjects were subjects with an antibody titer less than 110 EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV-16 and HPV-18 Geometric Mean Titers (GMT) (V5/J4 Monoclonal Inhibition Test)</measure>
    <time_frame>Month 0, 7, 12, 24</time_frame>
    <description>Titers were expressed as GMTs in ELISA units per milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive for Anti-HPV-16 and Anti-HPV-18 Antibodies Using Pseudovirion Based Neutralizing Assay (PBNA)</measure>
    <time_frame>At Month 0, 7, 12, 24, 36 and 48</time_frame>
    <description>Seropositivity was defined as subjects with a titer equal to or greater than 40.
Subjects with an antibody titer smaller than 40 prior to vaccination were seronegative prior to vaccination and subjects with a titer equal to or greater than 40 were seropositive prior to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Anti-HPV-16 and Anti-HPV-18 Antibodies Using Pseudovirion Based Neutralizing Assay (PBNA)</measure>
    <time_frame>At month 0, 7, 12, 24, 36 and 48</time_frame>
    <description>Titers were expressed as GMTs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Anti-HPV-16 in Subjects Without and With 6-month Persistent Infection</measure>
    <time_frame>At Month 7</time_frame>
    <description>GMT for anti-HPV-16 antibodies by ELISA in subjects with breakthrough persistent infections 6-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence Interval) was not calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects for Anti-HPV-16 Without and With 6-month Persistent Infection.</measure>
    <time_frame>At Month 7</time_frame>
    <description>Seroconversion rates for anti-HPV-16 antibodies by ELISA in subjects with breakthrough persistent infections 6-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence interval) was not calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Anti-HPV-16 in Subjects Without and With 12-month Persistent Infection</measure>
    <time_frame>At Month 7</time_frame>
    <description>GMTs for anti-HPV-16 antibodies by ELISA in subjects with breakthrough persistent infections 12-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects for Anti-HPV-16 Without and With 12-month Persistent Infection</measure>
    <time_frame>At Month 7</time_frame>
    <description>Seroconversion rates for anti-HPV-16 antibodies by ELISA in subjects with breakthrough persistent infections 12-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence Interval) was not calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Anti-HPV-18 in Subjects Without and With 6-month Persistent Infection</measure>
    <time_frame>At Month 7</time_frame>
    <description>GMTs for anti-HPV-18 antibodies by ELISA in subjects with breakthrough persistent infections 6-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects for Anti-HPV-18 Without and With 6-month Persistent Infection.</measure>
    <time_frame>At Month 7</time_frame>
    <description>Seroconversion rates for anti-HPV-18 antibodies by ELISA in subjects with breakthrough persistent infections 6-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence Interval) was not calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Anti-HPV-18 in Subjects Without and With 12-month Persistent Infection</measure>
    <time_frame>At Month 7</time_frame>
    <description>GMTs for anti-HPV-18 antibodies by ELISA in subjects with breakthrough persistent infections 12-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects for Anti-HPV-18 Without and With 12-month Persistent Infection</measure>
    <time_frame>At Month 7</time_frame>
    <description>Seroconversion rates for anti-HPV-18 antibodies by ELISA in subjects with breakthrough persistent infections 12-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence Interval) was not calculated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18729</enrollment>
  <condition>Infections, Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Cervarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Havrix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarixâ¢</intervention_name>
    <description>Intramuscular injection, 3 doses</description>
    <arm_group_label>Cervarix Group</arm_group_label>
    <other_name>GSK Biologicals HPV 16/18 VLP/AS04 vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Havrixâ¢-based investigational formulation</intervention_name>
    <description>Intramuscular injection, 3 doses</description>
    <arm_group_label>Havrix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A woman whom the investigator believes that she and/or her parents/legally acceptable
             representative can and will comply with the requirements of the protocol (e.g.,
             completion of the diary cards, return for follow-up visits).

          -  A woman between, and including, 15 and 25 years of age at the time of the first
             vaccination.

          -  Written informed consent must be obtained from the subject prior to enrollment (for
             subjects below the legal age of consent, written informed consent must be obtained
             from a parent or legal guardian of the subject and, in addition, the subject should
             sign and personally date a written informed assent).

          -  Subject must be free of obvious health problems as established by medical history and
             clinical examination before entering into the study.

          -  Subject must have a negative urine pregnancy test.

          -  Subject must be of non-childbearing potential or, if of childbearing potential, she
             must be abstinent or must be using adequate contraceptive precautions for 30 days
             prior to the first vaccination and must agree to continue such precautions for two
             months after completion of the vaccination series.

          -  Has had no more than 6 lifetime sexual partners prior to enrollment. This criterion
             may not be applicable in subjects less than 18 years of age, according to local
             regulatory/ethical requirements.

          -  Subject must have intact cervix.

        Exclusion Criteria:

          -  Pregnant or breastfeeding. Women must be at least 3 months post-pregnancy and not
             breastfeeding to enter the study.

          -  A woman planning to become pregnant or planning to discontinue contraceptive
             precautions during approximately the first nine months of the study (Months 0-8).

          -  Previous administration of components of the investigational vaccine.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days before and 30 days after (i.e. days 0-29) each dose of vaccine.
             Administration of some routine vaccines up to 8 days before each dose of study vaccine
             is allowed. Enrolment will be deferred until the subject is outside of specified
             window.

          -  Previous vaccination against human papillomavirus (HPV).

          -  History of vaccination against Hepatitis A or a known clinical history of Hepatitis A
             disease.

          -  History of having had colposcopy or has planned a colposcopy to evaluate an abnormal
             cervical cytology (Pap smear) test.

          -  Any medically diagnosed or suspected immunodeficient condition based on medical
             history and physical examination.

          -  History of allergic disease, suspected allergy or reactions likely to be exacerbated
             by any component of the study vaccines.

          -  Hypersensitivity to latex.

          -  Known acute or chronic, clinically significant pulmonary, cardiovascular, neurologic,
             hepatic or renal functional abnormality, as determined by previous physical
             examination or laboratory tests.

          -  History of chronic condition(s) requiring treatment.

          -  Received immunoglobulins and/or blood product within 90 days preceding enrollment.
             Enrollment will be deferred until the subject is outside of specified window.

          -  Acute disease at the time of enrolment.

          -  Heavy bleeding (menstruation or other) or heavy vaginal discharge in which a pelvic
             exam cannot be performed. Enrollment will be deferred until condition is resolved
             according to investigator's medical judgement.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Colorado</state>
        <zip>80027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arkansas City</city>
        <state>Kansas</state>
        <zip>67005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <zip>15106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>4001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carlton, Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <state>ParanÃ¡</state>
        <zip>80069-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Campinas</city>
        <state>SÃ£o Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Langley</city>
        <state>British Columbia</state>
        <zip>V3A 4H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1E 2C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 1C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1S 1C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beauport</city>
        <state>Quebec</state>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>02100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00610</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jyvaskyla</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kerava</city>
        <zip>04250</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kotka</city>
        <zip>48100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kouvola</city>
        <zip>45100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lahti</city>
        <zip>15110</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lappeenranta</city>
        <zip>53100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mikkeli</city>
        <zip>50100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rauma</city>
        <zip>26100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vaasa</city>
        <zip>65100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Wuerttemberg</state>
        <zip>76199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ravensburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rheinstetten</city>
        <state>Baden-Wuerttemberg</state>
        <zip>76287</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dietzenbach</city>
        <state>Hessen</state>
        <zip>63128</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>65936</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nordhausen</city>
        <state>Thueringen</state>
        <zip>99734</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41150</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cuenavaca</city>
        <state>Morelos</state>
        <zip>62430</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cavite</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Laguna</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Pinas City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Banos, Laguna</city>
        <zip>4027</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Makati City</city>
        <zip>1231</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>MÃ³stoles</city>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W1P 1LB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterloo, Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2005</study_first_submitted>
  <study_first_submitted_qc>July 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2005</study_first_posted>
  <results_first_submitted>November 30, 2009</results_first_submitted>
  <results_first_submitted_qc>December 16, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2010</results_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>580299/008</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>580299/008</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>580299/008</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>580299/008</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>580299/008</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>580299/008</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>580299/008</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 18729 subjects enrolled in the study, 64 subjects were not vaccinated. Within the 18665 subjects vaccinated, 21 subjects from 1 center were excluded from all analyses because of potential data discrepancies identified at this center. As a result, a total of 18644 subjects are reported as started in the participant flow.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Havrix Group</title>
          <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
        </group>
        <group group_id="P2">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9325"/>
                <participants group_id="P2" count="9319"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7811"/>
                <participants group_id="P2" count="7798"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1514"/>
                <participants group_id="P2" count="1521"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1080"/>
                <participants group_id="P2" count="1097"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="257"/>
                <participants group_id="P2" count="251"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="147"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Havrix Group</title>
          <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
        </group>
        <group group_id="B2">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9325"/>
            <count group_id="B2" value="9319"/>
            <count group_id="B3" value="18644"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.0" spread="3.12"/>
                    <measurement group_id="B2" value="20.0" spread="3.10"/>
                    <measurement group_id="B3" value="20.0" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9325"/>
                    <measurement group_id="B2" value="9319"/>
                    <measurement group_id="B3" value="18644"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection in Subjects HPV DNA Negative and Seronegative at Baseline or Overall (Any Serostatus at Baseline)</title>
        <description>CIN2+ was defined as CIN grades 2 and 3, endocervical adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done in:
DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
        <time_frame>Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post-dose 3</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects who had received 3 doses of study vaccine, who had a normal or low-grade cytology (i.e. negative or Atypical Squamous Cells of Undetermined Significance (ASC-US) or Low-grade Squamous Intraepithelial Lesion (LSIL)) at Month 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection in Subjects HPV DNA Negative and Seronegative at Baseline or Overall (Any Serostatus at Baseline)</title>
          <description>CIN2+ was defined as CIN grades 2 and 3, endocervical adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done in:
DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects who had received 3 doses of study vaccine, who had a normal or low-grade cytology (i.e. negative or Atypical Squamous Cells of Undetermined Significance (ASC-US) or Low-grade Squamous Intraepithelial Lesion (LSIL)) at Month 0.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7767"/>
                <count group_id="O2" value="7814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- &amp; sero- subjects (n= 7312, 7344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- &amp; sero- subjects (n= 6165, 6303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- &amp; sero- subjects (n= 6746, 6794)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (n= 7767, 7814)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (n= 7276, 7372)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (n= 7583, 7645)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against CIN2+ associated with HPV-16 or HPV-18 (by PCR) in HPV DNA negative and seronegative subjects at baseline, using conditional exact method. The VE was defined as follows: VE = 1-Rate Ratio (RR), where RR = incidence rate in HPV Group (vaccine)/ incidence rate in HAV Group (control); Incidence rate = n/T(per 100); n= number of subjects reporting at least one event in each group and T(years) = sum of follow-up period (censored at the first occurrence of an event) expressed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>1-Rate Ratio</param_type>
            <param_value>92.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>79.9</ci_lower_limit>
            <ci_upper_limit>98.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against CIN2+ associated with HPV-16 (by PCR) in HPV DNA negative and seronegative subjects at baseline, using conditional exact method. The VE was defined as follows: VE = 1-Rate Ratio (RR), where RR = incidence rate in HPV Group (vaccine)/ incidence rate in HAV Group (control); Incidence rate = n/T(per 100); n= number of subjects reporting at least one event in each group and T(years) = sum of follow-up period (censored at the first occurrence of an event) expressed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>1-Rate Ratio</param_type>
            <param_value>95.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.9</ci_lower_limit>
            <ci_upper_limit>99.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against CIN2+ associated with HPV-18 (by PCR) in HPV DNA negative and seronegative subjects at baseline, using conditional exact method. The VE was defined as follows: VE = 1-Rate Ratio (RR), where RR = incidence rate in HPV Group (vaccine)/ incidence rate in HAV Group (control); Incidence rate = n/T(per 100); n= number of subjects reporting at least one event in each group and T(years) = sum of follow-up period (censored at the first occurrence of an event) expressed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>1-Rate Ratio</param_type>
            <param_value>86.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>39.7</ci_lower_limit>
            <ci_upper_limit>98.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against CIN2+ for HPV-16 or HPV-18 (by PCR) in HPV DNA negative subjects at baseline, regardless of initial serostatus, using conditional exact method. The VE was defined as follows: VE = 1-Rate Ratio (RR), where RR = incidence rate in HPV Group (vaccine)/ incidence rate in HAV Group (control); Incidence rate = n/T(per 100); n= number of subjects reporting at least one event in each group and T(years) = sum of follow-up period (censored at the first occurrence of an event).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>1-Rate Ratio</param_type>
            <param_value>90.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>78.1</ci_lower_limit>
            <ci_upper_limit>96.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against CIN2+ for HPV-16 (by PCR) in HPV DNA negative subjects at baseline, regardless of initial serostatus, using conditional exact method. The VE was defined as follows: VE = 1-Rate Ratio (RR), where RR = incidence rate in HPV Group (vaccine)/ incidence rate in HAV Group (control); Incidence rate = n/T(per 100); n= number of subjects reporting at least one event in each group and T(years) = sum of follow-up period (censored at the first occurrence of an event).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>1-Rate Ratio</param_type>
            <param_value>92.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>79.3</ci_lower_limit>
            <ci_upper_limit>98.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against CIN2+ for HPV-18 (by PCR) in HPV DNA negative subjects at baseline, regardless of initial serostatus, using conditional exact method. The VE was defined as follows: VE = 1-Rate Ratio (RR), where RR = incidence rate in HPV Group (vaccine)/ incidence rate in HAV Group (control); Incidence rate = n/T(per 100); n= number of subjects reporting at least one event in each group and T(years) = sum of follow-up period (censored at the first occurrence of an event).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>1-Rate Ratio</param_type>
            <param_value>87.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44.1</ci_lower_limit>
            <ci_upper_limit>98.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection in Subjects HPV DNA Negative and Seronegative at Baseline or Overall (Any Serostatus at Baseline)</title>
        <description>CIN2+ was defined as CIN grades 2 and 3, endocervical adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done in subjects:
DNA- and sero-: HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
        <time_frame>at Month 48</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects who had received 3 doses of study vaccine, who had a normal or low-grade cytology (i.e. negative or Atypical Squamous Cells of Undetermined Significance (ASC-US) or Low-grade Squamous Intraepithelial Lesion (LSIL)) at Month 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection in Subjects HPV DNA Negative and Seronegative at Baseline or Overall (Any Serostatus at Baseline)</title>
          <description>CIN2+ was defined as CIN grades 2 and 3, endocervical adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done in subjects:
DNA- and sero-: HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects who had received 3 doses of study vaccine, who had a normal or low-grade cytology (i.e. negative or Atypical Squamous Cells of Undetermined Significance (ASC-US) or Low-grade Squamous Intraepithelial Lesion (LSIL)) at Month 0.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7760"/>
                <count group_id="O2" value="7806"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- &amp; sero- subjects (n= 7305, 7338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- &amp; sero- subjects (n= 6160, 6296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- &amp; sero- subjects (n= 6739, 6789)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (n= 7760, 7806)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (n= 7267, 7364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (n= 7577, 7638)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against CIN2+ associated with HPV-16 or HPV-18 (by PCR) in HPV DNA negative and seronegative subjects at baseline, using conditional exact method. The VE was defined as follows: VE = 1-Rate Ratio (RR), where RR = incidence rate in HPV Group (vaccine)/ incidence rate in HAV Group (control); Incidence rate = n/T(per 100); n= number of subjects reporting at least one event in each group and T(years) = sum of follow-up period (censored at the first occurrence of an event) expressed</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>1-Rate Ratio</param_type>
            <param_value>94.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.7</ci_lower_limit>
            <ci_upper_limit>98.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against CIN2+ associated with HPV-16 (by PCR) in HPV DNA negative and seronegative subjects at baseline, using conditional exact method. The VE was defined as follows: VE = 1-Rate Ratio (RR), where RR = incidence rate in HPV Group (vaccine)/ incidence rate in HAV Group (control); Incidence rate = n/T(per 100); n= number of subjects reporting at least one event in each group and T(years) = sum of follow-up period (censored at the first occurrence of an event) expressed</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>1-Rate Ratio</param_type>
            <param_value>97.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.0</ci_lower_limit>
            <ci_upper_limit>99.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against CIN2+ associated with HPV-18 (by PCR) in HPV DNA negative and seronegative subjects at baseline, using conditional exact method. The VE was defined as follows: VE = 1-Rate Ratio (RR), where RR = incidence rate in HPV Group (vaccine)/ incidence rate in HAV Group (control); Incidence rate = n/T(per 100); n= number of subjects reporting at least one event in each group and T(years) = sum of follow-up period (censored at the first occurrence of an event) expressed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>1-Rate Ratio</param_type>
            <param_value>87.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>57.2</ci_lower_limit>
            <ci_upper_limit>97.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against CIN2+ for HPV-16 or HPV-18 (by PCR) in HPV DNA negative subjects at baseline, regardless of initial serostatus, using conditional exact method. The VE was defined as follows: VE = 1-Rate Ratio (RR), where RR = incidence rate in HPV Group (vaccine)/ incidence rate in HAV Group (control); Incidence rate = n/T(per 100); n= number of subjects reporting at least one event in each group and T(years) = sum of follow-up period (censored at the first occurrence of an event).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>1-Rate Ratio</param_type>
            <param_value>93.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.3</ci_lower_limit>
            <ci_upper_limit>97.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against CIN2+ for HPV-16 (by PCR) in HPV DNA negative subjects at baseline, regardless of initial serostatus, using conditional exact method. The VE was defined as follows: VE = 1-Rate Ratio (RR), where RR = incidence rate in HPV Group (vaccine)/ incidence rate in HAV Group (control); Incidence rate = n/T(per 100); n= number of subjects reporting at least one event in each group and T(years) = sum of follow-up period (censored at the first occurrence of an event).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>1-Rate Ratio</param_type>
            <param_value>95.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.5</ci_lower_limit>
            <ci_upper_limit>98.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against CIN2+ for HPV-18 (by PCR) in HPV DNA negative subjects at baseline, regardless of initial serostatus, using conditional exact method. The VE was defined as follows: VE = 1-Rate Ratio (RR), where RR = incidence rate in HPV Group (vaccine)/ incidence rate in HAV Group (control); Incidence rate = n/T(per 100); n= number of subjects reporting at least one event in each group and T(years) = sum of follow-up period (censored at the first occurrence of an event).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>1-Rate Ratio</param_type>
            <param_value>87.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>59.2</ci_lower_limit>
            <ci_upper_limit>97.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
        <description>CIN1+ was defined as histopathologically-confirmed lesions including cervical intraepithelial neoplasia of grade 1 (CIN1), grade 2 (CIN2), grade 3 (CIN3), AIS and invasive cervical cancer.
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
        <time_frame>Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post dose 3</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
          <description>CIN1+ was defined as histopathologically-confirmed lesions including cervical intraepithelial neoplasia of grade 1 (CIN1), grade 2 (CIN2), grade 3 (CIN3), AIS and invasive cervical cancer.
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7767"/>
                <count group_id="O2" value="7814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- &amp; sero- (n= 7312, 7344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- &amp; sero- (n= 6165, 6303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- &amp; sero- (n= 6746, 6794)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (n= 7767, 7814)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (n= 7276, 7372)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (n= 7583, 7645)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and General Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include arthralgia, fatigue, fever (measured in degree celsius (Â°C) by axillary route), gastrointestinal symptoms, headache, myalgia, rash and urticaria.
Data are presented across the 3 doses.</description>
        <time_frame>Within 7 days after any vaccination</time_frame>
        <population>Analysis was performed on a safety subset of the Total vaccinated cohort, which included vaccinated subjects from certain sites. Data are presented for the total subset (total), then stratified subject HPV-16/18 DNA &amp; serostatus at baseline: DNA positive (DNA+) or negative (DNA-), ELISA seropositive (sero+) or seronegative (sero-).</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and General Symptoms</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include arthralgia, fatigue, fever (measured in degree celsius (Â°C) by axillary route), gastrointestinal symptoms, headache, myalgia, rash and urticaria.
Data are presented across the 3 doses.</description>
          <population>Analysis was performed on a safety subset of the Total vaccinated cohort, which included vaccinated subjects from certain sites. Data are presented for the total subset (total), then stratified subject HPV-16/18 DNA &amp; serostatus at baseline: DNA positive (DNA+) or negative (DNA-), ELISA seropositive (sero+) or seronegative (sero-).</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3081"/>
                <count group_id="O2" value="3078"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain, total (n= 3080, 3078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2403"/>
                    <measurement group_id="O2" value="2787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, sero+ or DNA+ (n= 827, 830)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="622"/>
                    <measurement group_id="O2" value="743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, sero- &amp; DNA- (n=2219,2211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1758"/>
                    <measurement group_id="O2" value="2013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, DNA+ (n= 212, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, total (n= 3080, 3078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="851"/>
                    <measurement group_id="O2" value="1349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, sero+ or DNA+ (n= 827, 830)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211"/>
                    <measurement group_id="O2" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, sero- &amp; DNA- (n=2219,2211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="630"/>
                    <measurement group_id="O2" value="1005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, DNA+ (n= 212, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, total (n= 3080, 3078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="609"/>
                    <measurement group_id="O2" value="1293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, sero+ or DNA+ (n= 827, 830)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, sero- &amp; DNA- (n=2219,2211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="454"/>
                    <measurement group_id="O2" value="959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, DNA+ (n= 212, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia, total (n=3081, 3078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="551"/>
                    <measurement group_id="O2" value="633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia, sero+ or DNA+ (n= 828, 830)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia, sero- &amp; DNA- (n=2219,2211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384"/>
                    <measurement group_id="O2" value="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia, DNA+ (n= 212, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, total (n=3081, 3078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1652"/>
                    <measurement group_id="O2" value="1771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, sero+ or DNA+ (n= 828, 830)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415"/>
                    <measurement group_id="O2" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, sero- &amp; DNA- (n=2219,2211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1215"/>
                    <measurement group_id="O2" value="1311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, DNA+ (n= 212, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever â¥ 37.5Â°C, total (n=3081, 3078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342"/>
                    <measurement group_id="O2" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever â¥ 37.5Â°C, sero+ or DNA+ (n= 828, 830)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever â¥ 37.5Â°C, sero- &amp; DNA- (n=2219,2211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236"/>
                    <measurement group_id="O2" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever â¥ 37.5Â°C, DNA+ (n= 212, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastro-intestinal symptoms, total (n=3081,3078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="847"/>
                    <measurement group_id="O2" value="856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastro-intestinal,sero+ or DNA+ (n= 828, 830)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastro-intestinal,sero- &amp; DNA- (n=2219,221</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="595"/>
                    <measurement group_id="O2" value="601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastro-intestinal symptoms, DNA+ (n= 212, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, total (n= 3081, 3078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1583"/>
                    <measurement group_id="O2" value="1668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, sero+ or DNA+ (n= 828, 830)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423"/>
                    <measurement group_id="O2" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, sero- &amp; DNA- (n=2219,2211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1141"/>
                    <measurement group_id="O2" value="1223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, DNA+ (n= 212, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, total (n= 3081, 3078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1381"/>
                    <measurement group_id="O2" value="1607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, sero+ or DNA+ (n= 828, 830)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347"/>
                    <measurement group_id="O2" value="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, sero- &amp; DNA- (n=2219, 2211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1019"/>
                    <measurement group_id="O2" value="1200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, DNA+ (n= 212, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash, total (n= 3081, 3078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash, sero+ or DNA+ (n= 828, 830)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash, sero- &amp;amp; DNA- (n=2219, 2211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash, DNA+ (n= 212, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria, total (n= 3081, 3078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244"/>
                    <measurement group_id="O2" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria, sero+ or DNA+ (n= 828, 830)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria, sero- &amp;amp; DNA- (n=2219, 2211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria, DNA+ (n= 212, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events</title>
        <description>Unsolicited adverse event (AE) covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>Within 30 days after any vaccination</time_frame>
        <population>Analysis was performed on the Safety Subset of the Total Vaccinated Cohort and stratified according to initial (Month 0) HPV-16/18 DNA Status and According to HPV-16 or -18 Serostatus.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events</title>
          <description>Unsolicited adverse event (AE) covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>Analysis was performed on the Safety Subset of the Total Vaccinated Cohort and stratified according to initial (Month 0) HPV-16/18 DNA Status and According to HPV-16 or -18 Serostatus.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3187"/>
                <count group_id="O2" value="3184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total (n=3187, 3184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1466"/>
                    <measurement group_id="O2" value="1448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero+ DNA+ (n=858, 854)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400"/>
                    <measurement group_id="O2" value="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero- DNA- (n=2289, 2290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1048"/>
                    <measurement group_id="O2" value="1049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+ (n=222, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Throughout the entire study period (Month 0 to Month 48)</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort. The data are presented stratified by initial (Month 0) HPV-16/18 DNA status and according to HPV-16 or 18 serostatus (by ELISA).</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort. The data are presented stratified by initial (Month 0) HPV-16/18 DNA status and according to HPV-16 or 18 serostatus (by ELISA).</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9325"/>
                <count group_id="O2" value="9319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total (n=9325, 9319)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="829"/>
                    <measurement group_id="O2" value="835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero + and DNA + (n=2419, 2409)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- and DNA- (n=6789, 6804)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="587"/>
                    <measurement group_id="O2" value="576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+ (n=649, 690)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting New Onset of Chronic Disease (NOCDs)</title>
        <description>NOCDs include autoimmune disorders, asthma, type I diabetes, allergies.</description>
        <time_frame>Throughout the entire study (Month 0 to 48)</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort and stratified according to initial (Month 0) HPV-16/18 DNA Status and According to HPV-16 or -18 Serostatus.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting New Onset of Chronic Disease (NOCDs)</title>
          <description>NOCDs include autoimmune disorders, asthma, type I diabetes, allergies.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort and stratified according to initial (Month 0) HPV-16/18 DNA Status and According to HPV-16 or -18 Serostatus.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9325"/>
                <count group_id="O2" value="9319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total (n= 9325, 9319)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307"/>
                    <measurement group_id="O2" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero+ and DNA+ (n= 2419, 2409)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero- and DNA- (n= 6789, 6804)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+ (n= 649, 690)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Medically Significant Conditions</title>
        <description>Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
        <time_frame>Throughout entire study period (Month 0 to Month 48)</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort and stratified according to initial (Month 0) HPV-16/18 DNA Status and According to HPV-16 or -18 Serostatus.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Medically Significant Conditions</title>
          <description>Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort and stratified according to initial (Month 0) HPV-16/18 DNA Status and According to HPV-16 or -18 Serostatus.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9325"/>
                <count group_id="O2" value="9319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total (n=9325, 9319)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3378"/>
                    <measurement group_id="O2" value="3298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero+ DNA+ (n= 2419, 2409)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="957"/>
                    <measurement group_id="O2" value="958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero- DNA- (n= 6789, 6804)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2378"/>
                    <measurement group_id="O2" value="2303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+ (n= 649, 690)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285"/>
                    <measurement group_id="O2" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Outcome of Pregnancies, Overall and Stratified by Initial (Month 0) HPV-16/18 DNA Status and According to HPV-16 or -18 Serostatus</title>
        <description>Pregnancy outcomes are normal infant, premature infant, abnormal infant, elective termination, therapeutic abortion, ectopic pregnancy, spontaneous abortion, still birth, lost to follow-up, no pregnancy/molar pregnancy, pregnancy ongoing.</description>
        <time_frame>Throughout the entire study period (Month 0 to Month 48)</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort and stratified according to initial (Month 0) HPV-16/18 DNA Status and According to HPV-16 or -18 Serostatus.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Outcome of Pregnancies, Overall and Stratified by Initial (Month 0) HPV-16/18 DNA Status and According to HPV-16 or -18 Serostatus</title>
          <description>Pregnancy outcomes are normal infant, premature infant, abnormal infant, elective termination, therapeutic abortion, ectopic pregnancy, spontaneous abortion, still birth, lost to follow-up, no pregnancy/molar pregnancy, pregnancy ongoing.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort and stratified according to initial (Month 0) HPV-16/18 DNA Status and According to HPV-16 or -18 Serostatus.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2257"/>
                <count group_id="O2" value="2257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total (n=2257, 2257), normal infant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1671"/>
                    <measurement group_id="O2" value="1642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total, premature birth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total, abnormal infant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total, elective termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total, therapeutic abortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total, ectopic pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total, spontaneous abortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                    <measurement group_id="O2" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total, still birth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total, lost to follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total, no pregnancy, molar pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total, pregnancy ongoing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero- DNA- (n=1553, 1540), normal infant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1164"/>
                    <measurement group_id="O2" value="1159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero- DNA-, premature birth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero- DNA-, abnormal infant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero- DNA-, elective termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero- DNA-, therapeutic abortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero- DNA-, ectopic pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero- DNA-, spontaneous abortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero- DNA -, still birth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero- DNA-, lost to follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero- DNA-, no pregnancy, molar pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero- DNA-, pregnancy ongoing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero+ DNA+ (n=676, 685), normal infant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="486"/>
                    <measurement group_id="O2" value="464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero+ DNA+, premature birth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero+ DNA+, abnormal infant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero+ DNA+, elective termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero+ DNA+, therapeutic abortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero+ DNA+, ectopic pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero+ DNA+, spontaneous abortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero+ DNA+, still birth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero+ DNA+, lost to follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero+ DNA+, no pregnancy, molar pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sero+ DNA+, pregnancy ongoing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+(n=162, 199), normal infant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+, premature infant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+, abnormal infant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+, elective termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+, therapeutic abortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+, ectopic pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+, spontaneous abortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+, still birth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+, lost to follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+, no pregnancy, molar pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNA+, pregnancy ongoing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18</title>
        <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
        <time_frame>Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post dose 3</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0. All subjects had at least 5 months of follow-up after Month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18</title>
          <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0. All subjects had at least 5 months of follow-up after Month 12</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7556"/>
                <count group_id="O2" value="7619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- &amp; sero- (n= 7122, 7177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="488"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- &amp; sero- (n= 6018, 6163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- &amp; sero- (n= 6567, 6642)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (n= 7556, 7619)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="540"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (n= 7085, 7196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (n= 7377, 7457)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18</title>
        <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
        <time_frame>at Month 48</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine, who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0. All subjects had at least 5 months of follow-up after Month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18</title>
          <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine, who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0. All subjects had at least 5 months of follow-up after Month 12</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7572"/>
                <count group_id="O2" value="7626"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- &amp;amp; sero- (n= 7137, 7182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="588"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- &amp; sero- (n= 6029, 6165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- &amp; sero- (n= 6581, 6649)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (n= 7572, 7626)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="654"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (n= 7099, 7202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="473"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (n= 7394, 7465)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types</title>
        <description>Oncogenic types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline regardless of initial serostatus.
HRW-HPV= All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HR-HPV= High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68</description>
        <time_frame>Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post dose 3</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0. All subjects had at least 5 months of follow-up after Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types</title>
          <description>Oncogenic types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline regardless of initial serostatus.
HRW-HPV= All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HR-HPV= High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0. All subjects had at least 5 months of follow-up after Month 12.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7640"/>
                <count group_id="O2" value="7665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 (n= 7085, 7196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (n= 7377, 7457)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31 (n= 7398, 7394)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-33 (n= 7496, 7527)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-35 (n= 7553, 7572)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV- 39 (n= 7411, 7423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-45 (n= 7540, 7587)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-51 (n= 7152, 7188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354"/>
                    <measurement group_id="O2" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-52 (n= 7221, 7280)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315"/>
                    <measurement group_id="O2" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-56 (n= 7435, 7460)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-58 (n= 7494, 7512)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-59 (n= 7514, 7528)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-66 (n= 7358, 7405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-68 (n= 7409, 7441)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRW-HPV (n= 7640, 7665)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1351"/>
                    <measurement group_id="O2" value="1207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR-HPV (n= 7640, 7665)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1607"/>
                    <measurement group_id="O2" value="1233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types</title>
        <description>Oncogenic types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline regardless of initial serostatus.
HRW-HPV = All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HR-HPV = High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68</description>
        <time_frame>at Month 48</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0. All subjects had at least 5 months of follow-up after Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types</title>
          <description>Oncogenic types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline regardless of initial serostatus.
HRW-HPV = All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HR-HPV = High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0. All subjects had at least 5 months of follow-up after Month 12.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7656"/>
                <count group_id="O2" value="7672"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 (n= 7099, 7202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="473"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (n= 7394, 7465)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31 (n= 7414, 7400)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-33 (n= 7513, 7534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-35 (n= 7569, 7579)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39 (n= 7428, 7429)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-45 (n= 7556, 7594)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-51 (n= 7165, 7190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416"/>
                    <measurement group_id="O2" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-52 (n= 7237, 7289)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374"/>
                    <measurement group_id="O2" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-56 (n= 7451, 7467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-58 (n= 7511, 7518)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-59 (n= 7530, 7536)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-66 (n= 7375, 7412)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-68 (n= 7424, 7450)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRW-HPV (n= 7656, 7672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1556"/>
                    <measurement group_id="O2" value="1399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR-HPV (n= 7656, 7672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1837"/>
                    <measurement group_id="O2" value="1424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
        <description>CIN1+ was defined as histopathologically-confirmed lesions including cervical intraepithelial neoplasia of grade 1 (CIN1), grade 2 (CIN2), grade 3 (CIN3), AIS and invasive cervical cancer.
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
        <time_frame>at Month 48</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
          <description>CIN1+ was defined as histopathologically-confirmed lesions including cervical intraepithelial neoplasia of grade 1 (CIN1), grade 2 (CIN2), grade 3 (CIN3), AIS and invasive cervical cancer.
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7760"/>
                <count group_id="O2" value="7806"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- &amp; sero- (n= 7305, 7338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- &amp; sero- (n= 6160, 6296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- &amp; sero- (n= 6739, 6789)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (n= 7760, 7806)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (n= 7267, 7364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (n= 7577, 7638)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Persistent Infection (12-month Definition) With HPV-16 or HPV-18</title>
        <description>Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type (by PCR) over a 12-month interval (evaluations were planned at approximately 6-month intervals).
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
        <time_frame>Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post dose 3</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0. All subjects had at least 10 months of follow-up after Month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Persistent Infection (12-month Definition) With HPV-16 or HPV-18</title>
          <description>Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type (by PCR) over a 12-month interval (evaluations were planned at approximately 6-month intervals).
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0. All subjects had at least 10 months of follow-up after Month 12</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7404"/>
                <count group_id="O2" value="7466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- &amp; sero- (n= 6984, 7035)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- &amp; sero- (n= 5903, 6052)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- &amp; sero- (n= 6440, 6508)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (n= 7404, 7466)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (n= 6941, 7057)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (n= 7231, 7307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Persistent Infection (12-month Definition) With HPV-16 or HPV-18</title>
        <description>Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type (by PCR) over a 12-month interval (evaluations were planned at approximately 6-month intervals).
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
        <time_frame>at Month 48</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0. All subjects had at least 10 months of follow-up after Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Persistent Infection (12-month Definition) With HPV-16 or HPV-18</title>
          <description>Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type (by PCR) over a 12-month interval (evaluations were planned at approximately 6-month intervals).
Detection was done in subjects:
DNA- and sero-: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and sero- for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0)
Overall: subjects HPV DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0. All subjects had at least 10 months of follow-up after Month 12.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7461"/>
                <count group_id="O2" value="7517"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- &amp; sero- (n= 7038, 7082)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- &amp; sero- (n= 5949, 6089)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- &amp; sero- (n= 6490, 6552)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (n= 7461, 7517)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (n= 6996, 7103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (n= 7288, 7356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
        <description>Oncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline regardless of initial serostatus.</description>
        <time_frame>Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post dose 3</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
          <description>Oncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline regardless of initial serostatus.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7764"/>
                <count group_id="O2" value="7782"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 (n= 7276, 7372)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (n= 7583, 7645)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31 (n= 7599, 7583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-33 (n= 7706, 7720)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-35 (n= 7764, 7768)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39 (n= 7614, 7609)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-45 (n= 7745, 7782)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-51 (n= 7352, 7363)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-52 (n= 7414, 7461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-56 (n= 7638, 7646)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-58 (n= 7702, 7709)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-59 (n=7723, 7720)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-66 (n= 7564, 7592)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-68 (n= 7614, 7633)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
        <description>Oncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline regardless of initial serostatus.</description>
        <time_frame>at Month 48</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
          <description>Oncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline regardless of initial serostatus.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7757"/>
                <count group_id="O2" value="7774"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 (n= 7267, 7364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (n= 7577, 7638)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31 (n= 7592, 7575)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-33 (n= 7700, 7712)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-35 (n= 7757, 7760)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39 (n= 7608, 7602)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-45 (n= 7738, 7774)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-51 (n= 7341, 7356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-52 (n= 7409, 7455)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-56 (n= 7631, 7638)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-58 (n= 7696, 7701)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-59 (n=7716, 7713)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-66 (n= 7559, 7583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-68 (n= 7606, 7626)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
        <description>CIN2+ was defined as histopathologically-confirmed lesions including cervical intraepithelial neoplasia of grade 2 (CIN2), grade 3 (CIN3), AIS and invasive cervical cancer.
Oncogenic types detected included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline, regardless of initial serostatus.</description>
        <time_frame>Up to the moment when 36 cases of CIN2+ lesions associated with HPV-16 or HPV-18 infection had been detected, including at least 15 cases of CIN2+ associated with HPV-18 infection. Mean follow-up was 34.9 months post dose 3</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
          <description>CIN2+ was defined as histopathologically-confirmed lesions including cervical intraepithelial neoplasia of grade 2 (CIN2), grade 3 (CIN3), AIS and invasive cervical cancer.
Oncogenic types detected included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline, regardless of initial serostatus.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7764"/>
                <count group_id="O2" value="7782"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 (n= 7276, 7372)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (n= 7583, 7645)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31 (n= 7599, 7583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-33 (n= 7706, 7720)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-35 (n= 7764, 7768)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39 (n= 7614, 7609)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-45 (n= 7745, 7782)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-51 (n= 7352, 7363)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-52 (n= 7414, 7461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-56 (n= 7638, 7646)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-58 (n=7702, 7709)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-59 (n= 7723, 7720)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-66 (n= 7564, 7592)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-68 (n= 7614, 7633)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
        <description>CIN2+ was defined as histopathologically-confirmed lesions including cervical intraepithelial neoplasia of grade 2 (CIN2), grade 3 (CIN3), AIS and invasive cervical cancer.
Oncogenic types detected included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline, regardless of initial serostatus.</description>
        <time_frame>at Month 48</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
          <description>CIN2+ was defined as histopathologically-confirmed lesions including cervical intraepithelial neoplasia of grade 2 (CIN2), grade 3 (CIN3), AIS and invasive cervical cancer.
Oncogenic types detected included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative at baseline, regardless of initial serostatus.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all evaluable subjects, who had received 3 doses of study vaccine and who had a normal or low-grade cytology (i.e. negative or ASC-US or LSIL) at Month 0.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7757"/>
                <count group_id="O2" value="7774"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 (n= 7267, 7364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (n= 7577, 7638)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31 (n= 7592, 7575)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-33 (n= 7700, 7712)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-35 (n= 7757, 7760)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39 (n= 7608, 7602)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-45 (n= 7738, 7774)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-51 (n= 7341, 7356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-52 (n= 7409, 7455)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-56 (n= 7631, 7638)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-58 (n=7696, 7701)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-59 (n= 7716, 7713)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-66 (n= 7559, 7583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-68 (n= 7606, 7626)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Anti-HPV-16 and Anti-HPV-18 Antibody Titers by ELISA in the Immunogenicity Subset, According to Initial (Month 0) HPV-16 or HPV-18 Serostatus</title>
        <description>Cut-off values assessed for seropositivity include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.
Results are presented for the total group and stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus by ELISA - seronegative (sero-) or seropositive (sero+)</description>
        <time_frame>At Months 6, 7, 12, 24, 36 &amp; 48</time_frame>
        <population>The analyses were performed on the ATP cohort for immunogenicity on evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects for Anti-HPV-16 and Anti-HPV-18 Antibody Titers by ELISA in the Immunogenicity Subset, According to Initial (Month 0) HPV-16 or HPV-18 Serostatus</title>
          <description>Cut-off values assessed for seropositivity include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.
Results are presented for the total group and stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus by ELISA - seronegative (sero-) or seropositive (sero+)</description>
          <population>The analyses were performed on the ATP cohort for immunogenicity on evaluable subjects for whom immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="898"/>
                <count group_id="O2" value="1036"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16, sero-, pre-vaccination (n= 750, 872)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, sero-, Month 6 (n= 738, 865)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, sero-, Month 7 (n= 740, 865)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, sero-, Month 12 (n= 719, 839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, sero-, Month 24 (n= 672, 797)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, sero-, Month 36 (n= 664, 784)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, sero-, Month 48 (n= 603, 746)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, sero+, pre-vaccination (n= 147, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, sero+, Month 6 (n= 139, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, sero+, Month 7 (n= 139, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, sero+, Month 12 (n= 134, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, sero+, Month 24 (n= 138, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, sero+, Month 36 (n= 127, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, sero+, Month 48 (n= 118, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, total, pre-vaccination (n= 897, 1036)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, total, Month 6 (n= 877, 1027)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="1025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, total, Month 7 (n= 879, 1028)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="1023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, total, Month 12 (n= 853, 993)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, total, Month 24 (n= 810, 943)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, total, Month 36 (n= 791, 926)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, total, Month 48 (n= 721, 891)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, sero-, pre-vaccination (n= 790,939)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, sero-, Month 6 (n= 771, 930)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, sero-, Month 7 (n= 772, 930)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, sero-, Month 12 (n= 748, 901)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, sero-, Month 24 (n= 698, 854)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, sero-, Month 36 (n= 691, 841)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, sero-, Month 48 (n= 633, 806)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, sero+, pre-vaccination (n= 108, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, sero+, Month 6 (n= 105, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, sero+, Month 7 (n= 105, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, sero+, Month 12 (n= 106, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, sero+, Month 24 (n= 102, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, sero+, Month 36 (n= 98, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, sero+, Month 48 (n= 91, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, total, pre-vaccination (n= 898, 1036)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, total, Month 6 (n= 876, 1027)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="1023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, total, Month 7 (n= 877, 1027)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="1022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, total, Month 12 (n= 854, 993)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, total, Month 24 (n= 800, 943)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, total, Month 36 (n= 789, 927)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, total, Month 48 (n= 724, 892)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HPV-16 and Anti-HPV-18 ELISA Titers in the Immunogenicity Subset</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) expressed as ELISA Units per milliliter (EL.U/mL).
GMTs are presented for the total group and also stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus by ELISA [seronegative (sero-) or seropositive (sero+)].</description>
        <time_frame>At Months 6, 7, 12, 24, 36 and 48</time_frame>
        <population>The analyses were performed on the ATP cohort for immunogenicity for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV-16 and Anti-HPV-18 ELISA Titers in the Immunogenicity Subset</title>
          <description>Titers are given as Geometric Mean Titers (GMTs) expressed as ELISA Units per milliliter (EL.U/mL).
GMTs are presented for the total group and also stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus by ELISA [seronegative (sero-) or seropositive (sero+)].</description>
          <population>The analyses were performed on the ATP cohort for immunogenicity for whom immunogenicity data were available.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="898"/>
                <count group_id="O2" value="1036"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16, sero-, pre-vaccination (n= 750, 872)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="4.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="4.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, sero-, Month 6 (n= 738, 865)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="4.2" upper_limit="4.5"/>
                    <measurement group_id="O2" value="630.7" lower_limit="591.6" upper_limit="672.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, sero-, Month 7 (n= 740, 865)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="4.2" upper_limit="4.6"/>
                    <measurement group_id="O2" value="9206.5" lower_limit="8609.4" upper_limit="9845.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, sero-, Month 12 (n= 719, 839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="4.2" upper_limit="4.4"/>
                    <measurement group_id="O2" value="3281.1" lower_limit="3064.5" upper_limit="3513.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, sero-, Month 24 (n= 672, 797)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="4.2" upper_limit="4.5"/>
                    <measurement group_id="O2" value="1592.0" lower_limit="1491.6" upper_limit="1699.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, sero-, Month 36 (n= 664, 784)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="4.2" upper_limit="4.5"/>
                    <measurement group_id="O2" value="1265.1" lower_limit="1184.8" upper_limit="1350.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, sero-, Month 48 (n= 603, 746)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="4.4" upper_limit="4.8"/>
                    <measurement group_id="O2" value="1174.3" lower_limit="1096.1" upper_limit="1258.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, sero+, pre-vaccination (n= 147, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" lower_limit="25.0" upper_limit="35.4"/>
                    <measurement group_id="O2" value="28.9" lower_limit="24.7" upper_limit="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, sero+, Month 6 (n= 139, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" lower_limit="19.9" upper_limit="29.8"/>
                    <measurement group_id="O2" value="1256.9" lower_limit="1030.1" upper_limit="1533.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, sero+, Month 7 (n= 139, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" lower_limit="17.4" upper_limit="27.0"/>
                    <measurement group_id="O2" value="6423.1" lower_limit="5486.3" upper_limit="7520.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, sero+, Month 12 (n= 134, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="16.3" upper_limit="25.1"/>
                    <measurement group_id="O2" value="2909.6" lower_limit="2504.3" upper_limit="3380.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, sero+, Month 24 (n= 138, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="15.0" upper_limit="23.2"/>
                    <measurement group_id="O2" value="1573.2" lower_limit="1356.7" upper_limit="1824.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, sero+, Month 36 (n= 127, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" lower_limit="14.0" upper_limit="22.2"/>
                    <measurement group_id="O2" value="1244.3" lower_limit="1068.9" upper_limit="1448.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, sero+, Month 48 (n= 118, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="14.5" upper_limit="23.0"/>
                    <measurement group_id="O2" value="1115.9" lower_limit="959.6" upper_limit="1297.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, total, pre-vaccination (n= 897, 1036)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="5.3" upper_limit="5.9"/>
                    <measurement group_id="O2" value="5.5" lower_limit="5.2" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, total, Month 6 (n= 877, 1027)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="5.4" upper_limit="6.1"/>
                    <measurement group_id="O2" value="703.2" lower_limit="659.5" upper_limit="749.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, total, Month 7 (n= 879, 1028)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="5.3" upper_limit="6.0"/>
                    <measurement group_id="O2" value="8695.7" lower_limit="8171.9" upper_limit="9253.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, total, Month 12 (n= 853, 993)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="5.2" upper_limit="5.8"/>
                    <measurement group_id="O2" value="3220.5" lower_limit="3026.4" upper_limit="3427.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, total, Month 24 (n= 810, 943)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="5.3" upper_limit="5.9"/>
                    <measurement group_id="O2" value="1589.1" lower_limit="1497.2" upper_limit="1686.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, total, Month 36 (n=791, 926)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="5.1" upper_limit="5.8"/>
                    <measurement group_id="O2" value="1261.9" lower_limit="1188.3" upper_limit="1340.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16, total, Month 48 (n=721, 891)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="5.4" upper_limit="6.1"/>
                    <measurement group_id="O2" value="1164.6" lower_limit="1093.9" upper_limit="1239.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, sero-, pre-vaccination (n=790, 939)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="3.5" upper_limit="3.5"/>
                    <measurement group_id="O2" value="3.5" lower_limit="3.5" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, sero-, Month 6 (n=771, 930)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="3.6" upper_limit="3.8"/>
                    <measurement group_id="O2" value="542.7" lower_limit="510.2" upper_limit="577.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, sero-, Month 7 (n= 772, 930)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="3.6" upper_limit="3.9"/>
                    <measurement group_id="O2" value="4741.3" lower_limit="4452.2" upper_limit="5049.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, sero-, Month 12 (n= 748, 901)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="3.7" upper_limit="3.9"/>
                    <measurement group_id="O2" value="1521.7" lower_limit="1431.0" upper_limit="1618.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, sero-, Month 24 (n= 698, 854)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="3.7" upper_limit="3.9"/>
                    <measurement group_id="O2" value="704.4" lower_limit="658.4" upper_limit="753.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, sero-, Month 36 (n= 691, 841)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="3.6" upper_limit="3.8"/>
                    <measurement group_id="O2" value="534.3" lower_limit="498.9" upper_limit="572.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, sero-, Month 48 (n= 633, 806)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="3.7" upper_limit="3.9"/>
                    <measurement group_id="O2" value="476.2" lower_limit="443.2" upper_limit="511.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, sero+, pre-vaccination (n= 108, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" lower_limit="18.9" upper_limit="29.1"/>
                    <measurement group_id="O2" value="24.8" lower_limit="20.1" upper_limit="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, sero+, Month 6 (n= 105, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" lower_limit="15.2" upper_limit="25.4"/>
                    <measurement group_id="O2" value="903.8" lower_limit="714.0" upper_limit="1144.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, sero+, Month 7 (n= 105, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" lower_limit="16.2" upper_limit="26.8"/>
                    <measurement group_id="O2" value="4135.7" lower_limit="3548.6" upper_limit="4819.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, sero+, Month 12 (n= 106, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" lower_limit="15.5" upper_limit="25.5"/>
                    <measurement group_id="O2" value="1509.5" lower_limit="1271.3" upper_limit="1792.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, sero+, Month 24 (n= 102, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" lower_limit="14.6" upper_limit="24.4"/>
                    <measurement group_id="O2" value="745.6" lower_limit="620.1" upper_limit="896.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, sero+, Month 36 (n= 98, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" lower_limit="12.8" upper_limit="22.1"/>
                    <measurement group_id="O2" value="580.9" lower_limit="475.0" upper_limit="710.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, sero+, Month 48 (n= 91, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="12.6" upper_limit="21.6"/>
                    <measurement group_id="O2" value="510.6" lower_limit="415.7" upper_limit="627.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, total, pre-vaccination (n= 898, 1036)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="4.2" upper_limit="4.6"/>
                    <measurement group_id="O2" value="4.2" lower_limit="4.0" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, total, Month 6 (n= 876, 1027)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="4.3" upper_limit="4.8"/>
                    <measurement group_id="O2" value="569.5" lower_limit="536.0" upper_limit="605.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, total, Month 7 (n= 877, 1027)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="4.4" upper_limit="4.9"/>
                    <measurement group_id="O2" value="4680.5" lower_limit="4413.4" upper_limit="4963.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, total, Month 12 (n= 854, 993)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="4.4" upper_limit="4.9"/>
                    <measurement group_id="O2" value="1520.5" lower_limit="1435.0" upper_limit="1611.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, total, Month 24 (n= 800, 943)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="4.4" upper_limit="4.9"/>
                    <measurement group_id="O2" value="708.2" lower_limit="664.6" upper_limit="754.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, total, Month 36 (n=789, 927)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="4.3" upper_limit="4.8"/>
                    <measurement group_id="O2" value="538.5" lower_limit="504.7" upper_limit="574.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18, total, Month 48 (n=724, 892)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="4.3" upper_limit="4.8"/>
                    <measurement group_id="O2" value="479.4" lower_limit="448.0" upper_limit="513.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPV-16 and HPV-18 Seroconversion (V5/J4 Monoclonal Inhibition Test)</title>
        <description>HPV-16 V5 cut-off was defined as greater than or equal to 41 ELU/mL. Only seronegative subjects were analysed. Seronegative subjects are subjects who had an antibody titer of less than 41 ELU/mL before vaccination.
HPV-18 J4 cut-off was defined as greater than or equal to 110 EL.U/mL. Both seropositive and seronegative subjects were included in the analysis. Seropositive subjects were subjects with an antibody titer of greater than or equal to 110 EL.U/mL. Seronegative subjects were subjects with an antibody titer less than 110 EL.U/mL.</description>
        <time_frame>Month 0, 7, 12 and 24</time_frame>
        <population>Analyses was performed on the Total Vaccinated Cohort on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>HPV-16 and HPV-18 Seroconversion (V5/J4 Monoclonal Inhibition Test)</title>
          <description>HPV-16 V5 cut-off was defined as greater than or equal to 41 ELU/mL. Only seronegative subjects were analysed. Seronegative subjects are subjects who had an antibody titer of less than 41 ELU/mL before vaccination.
HPV-18 J4 cut-off was defined as greater than or equal to 110 EL.U/mL. Both seropositive and seronegative subjects were included in the analysis. Seropositive subjects were subjects with an antibody titer of greater than or equal to 110 EL.U/mL. Seronegative subjects were subjects with an antibody titer less than 110 EL.U/mL.</description>
          <population>Analyses was performed on the Total Vaccinated Cohort on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-vaccination V5 HPV-16 (n= 17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 V5 HPV-16 (n= 17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 V5 HPV-16 (n= 5, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 V5 HPV-16 (n=17, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-vaccination J4 HPV-18 (n= 17, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 J4 HPV-18 (n= 17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 J4 HPV-18 (n= 5, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 V5 HPV-18 (n=17, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPV-16 and HPV-18 Geometric Mean Titers (GMT) (V5/J4 Monoclonal Inhibition Test)</title>
        <description>Titers were expressed as GMTs in ELISA units per milliliter (EL.U/mL).</description>
        <time_frame>Month 0, 7, 12, 24</time_frame>
        <population>The analyses was performed on the Total Vaccinated cohort on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>HPV-16 and HPV-18 Geometric Mean Titers (GMT) (V5/J4 Monoclonal Inhibition Test)</title>
          <description>Titers were expressed as GMTs in ELISA units per milliliter (EL.U/mL).</description>
          <population>The analyses was performed on the Total Vaccinated cohort on subjects with available results.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-vaccination V5 HPV-16 (n= 17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" lower_limit="20.5" upper_limit="20.5"/>
                    <measurement group_id="O2" value="20.5" lower_limit="20.5" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 V5 HPV-16 (n= 17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" lower_limit="20.5" upper_limit="20.5"/>
                    <measurement group_id="O2" value="816.7" lower_limit="472.5" upper_limit="1411.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 V5 HPV-16 (n= 5, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" lower_limit="20.5" upper_limit="20.5"/>
                    <measurement group_id="O2" value="173.5" lower_limit="25.1" upper_limit="1199.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 V5 HPV-16 (n=17, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" lower_limit="20.5" upper_limit="20.5"/>
                    <measurement group_id="O2" value="163.3" lower_limit="104.0" upper_limit="256.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-vaccination J4 HPV-18 (n= 17, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" lower_limit="55.0" upper_limit="55.0"/>
                    <measurement group_id="O2" value="57.7" lower_limit="52.1" upper_limit="63.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 J4 HPV-18 (n= 17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" lower_limit="55.0" upper_limit="55.0"/>
                    <measurement group_id="O2" value="679.2" lower_limit="423.6" upper_limit="1088.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 J4 HPV-18 (n= 5, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" lower_limit="35.0" upper_limit="144.2"/>
                    <measurement group_id="O2" value="83.6" lower_limit="0.4" upper_limit="17024.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 V5 HPV-18 (n=17, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1" lower_limit="51.7" upper_limit="65.2"/>
                    <measurement group_id="O2" value="139.5" lower_limit="90.5" upper_limit="215.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive for Anti-HPV-16 and Anti-HPV-18 Antibodies Using Pseudovirion Based Neutralizing Assay (PBNA)</title>
        <description>Seropositivity was defined as subjects with a titer equal to or greater than 40.
Subjects with an antibody titer smaller than 40 prior to vaccination were seronegative prior to vaccination and subjects with a titer equal to or greater than 40 were seropositive prior to vaccination.</description>
        <time_frame>At Month 0, 7, 12, 24, 36 and 48</time_frame>
        <population>The analyses were performed on the ATP cohort for immunogenicity which included subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive for Anti-HPV-16 and Anti-HPV-18 Antibodies Using Pseudovirion Based Neutralizing Assay (PBNA)</title>
          <description>Seropositivity was defined as subjects with a titer equal to or greater than 40.
Subjects with an antibody titer smaller than 40 prior to vaccination were seronegative prior to vaccination and subjects with a titer equal to or greater than 40 were seropositive prior to vaccination.</description>
          <population>The analyses were performed on the ATP cohort for immunogenicity which included subjects for whom immunogenicity data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-vaccination HPV-16 (n= 44, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 HPV-16 (n= 44, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 HPV-16 (n= 43, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 HPV-16 (n= 40, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 HPV-16 (n= 33, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 HPV-16 (n= 33, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-vaccination HPV-18 (n= 47, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 HPV-18 (n= 44, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 HPV-18 (n= 43, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 HPV-18 (n= 40, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 HPV-18 (n= 33, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 HPV-18 (n= 33, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Anti-HPV-16 and Anti-HPV-18 Antibodies Using Pseudovirion Based Neutralizing Assay (PBNA)</title>
        <description>Titers were expressed as GMTs.</description>
        <time_frame>At month 0, 7, 12, 24, 36 and 48</time_frame>
        <population>The analyses were performed on the ATP cohort for immunogenicity for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Havrix Group</title>
            <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Anti-HPV-16 and Anti-HPV-18 Antibodies Using Pseudovirion Based Neutralizing Assay (PBNA)</title>
          <description>Titers were expressed as GMTs.</description>
          <population>The analyses were performed on the ATP cohort for immunogenicity for whom immunogenicity data were available.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-vaccination HPV-16 (n= 44, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 HPV-16 (n= 44, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="27364.8" lower_limit="19780.1" upper_limit="37857.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 HPV-16 (n= 43, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="8385.9" lower_limit="5857.3" upper_limit="12006.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 HPV-16 (n= 40, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="3647.4" lower_limit="2586.5" upper_limit="5143.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 HPV-16 (n= 33, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="2245.1" lower_limit="1616.6" upper_limit="3117.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 HPV-16 (n= 33, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="1931.1" lower_limit="1294.4" upper_limit="2880.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-vaccination HPV-18 (n= 47, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 HPV-18 (n= 44, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="9052.7" lower_limit="6851.8" upper_limit="11960.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 HPV-18 (n= 43, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="1889.9" lower_limit="1316.0" upper_limit="2714.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 HPV-18 (n= 40, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="1695.6" lower_limit="1200.7" upper_limit="2394.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 HPV-18 (n= 33, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="1326.9" lower_limit="948.0" upper_limit="1857.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 HPV-18 (n= 33, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" lower_limit="18.6" upper_limit="30.4"/>
                    <measurement group_id="O2" value="1078.1" lower_limit="714.9" upper_limit="1625.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Anti-HPV-16 in Subjects Without and With 6-month Persistent Infection</title>
        <description>GMT for anti-HPV-16 antibodies by ELISA in subjects with breakthrough persistent infections 6-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence Interval) was not calculated.</description>
        <time_frame>At Month 7</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-16 DNA negative and seronegative at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group Without HPV-16 6-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6 and who did not present 6-Month persistent infection with HPV-16.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group With HPV-16 6-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6, who presented 6-Month persistent infection with HPV-16.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Anti-HPV-16 in Subjects Without and With 6-month Persistent Infection</title>
          <description>GMT for anti-HPV-16 antibodies by ELISA in subjects with breakthrough persistent infections 6-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence Interval) was not calculated.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-16 DNA negative and seronegative at baseline.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1123"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7667.34" lower_limit="7212.13" upper_limit="8151.29"/>
                    <measurement group_id="O2" value="6986.30" lower_limit="5692.83" upper_limit="8573.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio of anti-HPV-16 GMTs at Month 7 (by ELISA) in subjects without 6-month persistent infection compared to subjects with 6-month persistent infection</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3910</p_value>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.798</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.476</ci_lower_limit>
            <ci_upper_limit>1.337</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects for Anti-HPV-16 Without and With 6-month Persistent Infection.</title>
        <description>Seroconversion rates for anti-HPV-16 antibodies by ELISA in subjects with breakthrough persistent infections 6-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence interval) was not calculated.</description>
        <time_frame>At Month 7</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-16 DNA negative and seronegative at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group Without HPV-16 6-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6 and who did not present 6-Month persistent infection with HPV-16.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group With HPV-16 6-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6, who presented 6-Month persistent infection with HPV-16.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects for Anti-HPV-16 Without and With 6-month Persistent Infection.</title>
          <description>Seroconversion rates for anti-HPV-16 antibodies by ELISA in subjects with breakthrough persistent infections 6-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence interval) was not calculated.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-16 DNA negative and seronegative at baseline.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1123"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1118"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Anti-HPV-16 in Subjects Without and With 12-month Persistent Infection</title>
        <description>GMTs for anti-HPV-16 antibodies by ELISA in subjects with breakthrough persistent infections 12-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections.</description>
        <time_frame>At Month 7</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-16 DNA negative and seronegative at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group Without HPV-16 12-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6, without 12 Month persistent infection with HPV-16.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group With HPV-16 12-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6, with 12 Month persistent infection with HPV-16.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Anti-HPV-16 in Subjects Without and With 12-month Persistent Infection</title>
          <description>GMTs for anti-HPV-16 antibodies by ELISA in subjects with breakthrough persistent infections 12-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-16 DNA negative and seronegative at baseline.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1120"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7683.56" lower_limit="7229.22" upper_limit="8166.44"/>
                    <measurement group_id="O2" value="6839.71" lower_limit="5362.44" upper_limit="8723.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio of anti-HPV-16 GMTs at Month 7 (by ELISA) in subjects without 12-month persistent infection compared to subjects with 12-month persistent infection.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3796</p_value>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.778</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.444</ci_lower_limit>
            <ci_upper_limit>1.362</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects for Anti-HPV-16 Without and With 12-month Persistent Infection</title>
        <description>Seroconversion rates for anti-HPV-16 antibodies by ELISA in subjects with breakthrough persistent infections 12-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence Interval) was not calculated.</description>
        <time_frame>At Month 7</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-16 DNA negative and seronegative at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group Without HPV-16 12-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6, without 12 Month persistent infection with HPV-16.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group With HPV-16 12-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6, with 12 Month persistent infection with HPV-16.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects for Anti-HPV-16 Without and With 12-month Persistent Infection</title>
          <description>Seroconversion rates for anti-HPV-16 antibodies by ELISA in subjects with breakthrough persistent infections 12-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence Interval) was not calculated.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-16 DNA negative and seronegative at baseline.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1120"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1115"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Anti-HPV-18 in Subjects Without and With 6-month Persistent Infection</title>
        <description>GMTs for anti-HPV-18 antibodies by ELISA in subjects with breakthrough persistent infections 6-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections.</description>
        <time_frame>At Month 7</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-18 DNA negative and seronegative at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group Without HPV-18 6-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6 and who did not present 6-Month persistent infection with HPV-18.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group With HPV-18 6-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6, who presented 6-Month persistent infection with HPV-18.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Anti-HPV-18 in Subjects Without and With 6-month Persistent Infection</title>
          <description>GMTs for anti-HPV-18 antibodies by ELISA in subjects with breakthrough persistent infections 6-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-18 DNA negative and seronegative at baseline.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1248"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3963.50" lower_limit="3750.71" upper_limit="4188.37"/>
                    <measurement group_id="O2" value="2945.69" lower_limit="2271.74" upper_limit="3819.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio of anti-HPV-18 GMTs at Month 7 (by ELISA) in subjects without 6-month persistent infection compared to subjects with 6-month persistent infection.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1035</p_value>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.610</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.337</ci_lower_limit>
            <ci_upper_limit>1.106</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects for Anti-HPV-18 Without and With 6-month Persistent Infection.</title>
        <description>Seroconversion rates for anti-HPV-18 antibodies by ELISA in subjects with breakthrough persistent infections 6-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence Interval) was not calculated.</description>
        <time_frame>At Month 7</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-18 DNA negative and seronegative at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group Without HPV-18 6-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6 and who did not present 6-Month persistent infection with HPV-18.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group With HPV-18 6-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6, who presented 6-Month persistent infection with HPV-18.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects for Anti-HPV-18 Without and With 6-month Persistent Infection.</title>
          <description>Seroconversion rates for anti-HPV-18 antibodies by ELISA in subjects with breakthrough persistent infections 6-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence Interval) was not calculated.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-18 DNA negative and seronegative at baseline.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1248"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1242"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Anti-HPV-18 in Subjects Without and With 12-month Persistent Infection</title>
        <description>GMTs for anti-HPV-18 antibodies by ELISA in subjects with breakthrough persistent infections 12-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections.</description>
        <time_frame>At Month 7</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-18 DNA negative and seronegative at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group Without HPV-18 12-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6 and who did not present 12-Month persistent infection with HPV-18.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group With HPV-18 12-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6, who presented 12-Month persistent infection with HPV-18.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Anti-HPV-18 in Subjects Without and With 12-month Persistent Infection</title>
          <description>GMTs for anti-HPV-18 antibodies by ELISA in subjects with breakthrough persistent infections 12-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-18 DNA negative and seronegative at baseline.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3965.67" lower_limit="3753.09" upper_limit="4190.29"/>
                    <measurement group_id="O2" value="3063.23" lower_limit="2261.65" upper_limit="4148.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio of anti-HPV-18 GMTs at Month 7 (by ELISA) in subjects without 12-month persistent infection compared to subjects with 12-month persistent infection.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2111</p_value>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.635</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.312</ci_lower_limit>
            <ci_upper_limit>1.293</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects for Anti-HPV-18 Without and With 12-month Persistent Infection</title>
        <description>Seroconversion rates for anti-HPV-18 antibodies by ELISA in subjects with breakthrough persistent infections 12-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence Interval) was not calculated.</description>
        <time_frame>At Month 7</time_frame>
        <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-18 DNA negative and seronegative at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group Without HPV-18 12-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6 and who did not present 12-Month persistent infection with HPV-18.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix Group With HPV-18 12-Month Persistent Infection</title>
            <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6, who presented 12-Month persistent infection with HPV-18.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects for Anti-HPV-18 Without and With 12-month Persistent Infection</title>
          <description>Seroconversion rates for anti-HPV-18 antibodies by ELISA in subjects with breakthrough persistent infections 12-month definition, were compared to those in a matched set of subjects without breakthrough persistent infections. Due to the lack of seronegative subjects at Month 7, the hazard ratio (and Confidence Interval) was not calculated.</description>
          <population>The analysis was based on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available, only on subjects HPV-18 DNA negative and seronegative at baseline.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1243"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1237"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited symptoms during the 7-day post-vaccination period, Unsolicited AEs during the 30-day post-vaccination period, SAEs during the entire FU period.</time_frame>
      <desc>Results presented per group consist of a summary of the events (SAEs and AEs other than SAEs, respectively) reported, compiling overall number of subjects with events across the different periods of assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Havrix Group</title>
          <description>Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrixâ¢-based investigational formulation) at Months 0, 1 and 6.</description>
        </group>
        <group group_id="E2">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of Cervarixâ¢ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="829" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="835" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hyperchromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Wolff-parkinson-white syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Coarctation of the aorta</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Thyroglossal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Deafness bilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Basedowâs disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cyclic vomiting syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ileitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Intestinal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Malocclusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Mouth cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Reflux gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Tooth malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gallbladder pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Endometritis decidual</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Peritonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Post abortion infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abortion infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Epidemic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gynaecological chlamydia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hepatitis a</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Acquired immunodeficiency syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bacterial toxaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bartholinâs abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bone tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Epstein-barr virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Extrapulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Eye infection toxoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Haemorrhagic fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hepatitis c</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Herpes oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Induced abortion infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Infection parasitic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Neuroborreliosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Parotid abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Peritoneal tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Sweat gland infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Tonsillitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Trichomoniasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abortion induced incomplete</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Accidental needle stick</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abortion induced complete complicated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Colon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Diaphragmatic injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ilium fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Snake bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ulnar nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Uterine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Uterine rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Whiplash injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gestational diabetes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ligament disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Teratoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Benign hydatidiform mole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Astrocytoma malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Astrocytoma, low grade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bone sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the appendix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Gestational trophoblastic tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Anoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Benign intracranial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Intracranial venous sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pleocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Blighted ovum</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Intra-uterine death</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pregnancy induced hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Premature separation of placenta</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Chorioamnionitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abortion incomplete</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Retained products of conception</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ruptured ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Breech presentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Placenta praevia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Retained placenta or membranes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abortion complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Antepartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Arrested labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cephalo-pelvic disproportion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Face presentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>False labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Foetal growth retardation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Imminent abortion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Induced labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Obstructed labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Placenta accreta</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Placenta praevia haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Postpartum uterine subinvolution</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Prolonged labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Small for dates baby</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Uterine inversion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Anorexia nervosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bipolar ii disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bulimia nervosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Dissociative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Dysthymic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Emotional distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Generalized anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Histrionic personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Panic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Postpartum depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis membranoproliferative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bartholinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Fallopian tube cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ovarian cyst torsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Parovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Bartholinâs cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ovarian adhesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Ovarian torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Polycystic ovaries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Uterine atony</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Uterine malposition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Apnoeic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Rhinitis hypertrophic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Henoch-schonlein purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pyoderma gangrenosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Stevens-johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Urticaria chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Homicide</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Breech extraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Nail operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2403" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="2787" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at injection site</sub_title>
                <counts group_id="E1" subjects_affected="2403" subjects_at_risk="3080"/>
                <counts group_id="E2" subjects_affected="2787" subjects_at_risk="3078"/>
              </event>
              <event>
                <sub_title>Redness at injection site</sub_title>
                <counts group_id="E1" subjects_affected="851" subjects_at_risk="3080"/>
                <counts group_id="E2" subjects_affected="1349" subjects_at_risk="3078"/>
              </event>
              <event>
                <sub_title>Swelling at injection site</sub_title>
                <counts group_id="E1" subjects_affected="609" subjects_at_risk="3080"/>
                <counts group_id="E2" subjects_affected="1293" subjects_at_risk="3078"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="551" subjects_at_risk="3081"/>
                <counts group_id="E2" subjects_affected="633" subjects_at_risk="3078"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1652" subjects_at_risk="3081"/>
                <counts group_id="E2" subjects_affected="1771" subjects_at_risk="3078"/>
              </event>
              <event>
                <sub_title>Fever â¥ 37.5 degrees Celsius</sub_title>
                <counts group_id="E1" subjects_affected="342" subjects_at_risk="3081"/>
                <counts group_id="E2" subjects_affected="385" subjects_at_risk="3078"/>
              </event>
              <event>
                <sub_title>Gastro-intestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="847" subjects_at_risk="3081"/>
                <counts group_id="E2" subjects_affected="856" subjects_at_risk="3078"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1583" subjects_at_risk="3081"/>
                <counts group_id="E2" subjects_affected="1668" subjects_at_risk="3078"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1381" subjects_at_risk="3081"/>
                <counts group_id="E2" subjects_affected="1607" subjects_at_risk="3078"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="258" subjects_at_risk="3081"/>
                <counts group_id="E2" subjects_affected="314" subjects_at_risk="3078"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="244" subjects_at_risk="3081"/>
                <counts group_id="E2" subjects_affected="300" subjects_at_risk="3078"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="176" subjects_at_risk="3187"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="3184"/>
              </event>
              <event>
                <sub_title vocab="MedRA">Gynaecological Chlamydia infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1085" subjects_at_risk="9325"/>
                <counts group_id="E2" subjects_affected="1035" subjects_at_risk="9319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="250" subjects_at_risk="3187"/>
                <counts group_id="E2" subjects_affected="228" subjects_at_risk="3184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

